The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors
Open accessAbstract
Background: Treatment with immune checkpoint inhibitors (ICIs) targeting CTLA-4 and the PD-1/PD-L1 axis is effective against many cancer types. However, due in part to unresponsiveness or acquired resistance, not all patients experience a durable response to ICIs. HBI-8000 is a novel, orally bioavailable class I selective histone deacetylase inhibitor that directly modifies antitumor activity by inducing apoptosis, cell cycle arrest, and resensitization to apoptotic stimuli in adult T cell lymphoma patients. We hypothesized that HBI-8000 functions as an epigenetic immunomodulator to reprogram the tumor microenvironment from immunologically cold (nonresponsive) to hot (responsive). Method: Mice bearing syngeneic tumors (MC38 and CT26 murine colon carcinoma and A20 B-cell lymphoma were treated daily with HBI-8000 (orally), alone or in combination with PD-1, PD-1 L, or CTLA-4 antibodies. MC38 tumors were also analyzed in nanoString gene expression analysis. Results: HBI-8000 augmented the activity of ICI antibodies targeting either PD-1, PD-L1 or CTLA-4, and significantly increased tumor regression (p < 0.05) in the above models. Gene expression analysis of the treated MC38 tumors revealed significant changes in mRNA expression of immune checkpoints, with enhanced dendritic cell and antigen-presenting cell functions, and modulation of MHC class I and II molecules. Conclusions: These findings suggest that HBI-8000 mediates epigenetic modifications in the tumor microenvironment, leading to improved efficacy of ICIs, and provide strong rationale for combination therapies with ICIs and HBI-8000 in the clinical setting. Precis: As an HDACi, HBI-8000 plays an important role in priming the immune system in the tumor microenvironment. The current preclinical data further justifies testing combination of HBI-8000 and ICIs in the clinic.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Several previous studies have demonstrated that inhibition of HDAC enzymes by less-selective compounds can lead to increases in antigen presentation, as well as changes to intratumoral T-cell populations.
“Several previous studies have demonstrated that inhibition of HDAC enzymes by less-selective compounds can lead to increases in antigen presentation, as well as changes to intratumoral T-cell populations (40–43).”
From TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i> -Mutant Tumors to Anti–PD-1 Immunotherapy (2025) · cites this paper as [42]
The Results report increased expression of MHC genes relevant to antigen presentation after HBI-8000 treatment, and the Discussion reports increased CD8 expression in tumor-infiltrating lymphocytes when HBI-8000 was combined with checkpoint antibodies (page numbers unavailable). These findings support the general immune effects, but the paper identifies HBI-8000 as a class I-selective inhibitor; it does not establish the claim specifically for less-selective compounds. (LLM, conf=0.86)
Experimental — accuracy not yet measuredPreclinically, entinostat and domatinostat have demonstrated immune-mediated antitumor effects.
“Preclinically, these molecules have also demonstrated immune-mediated antitumor effects (41, 42, 45).”
From TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes <i>STK11</i> -Mutant Tumors to Anti–PD-1 Immunotherapy (2025) · cites this paper as [42]
HDAC inhibitor combined with α-PD-1/PD-L1 has shown a synergistic antitumor effect in murine tumor models.
“HDAC inhibitor combined with α-PD-1/PD-L1 has shown a synergistic antitumor effect in murine tumor models [329–331].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [331]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · see citing works
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · see citing works
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · see citing works
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · see citing works
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788 · see citing works
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · see citing works
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135 · see citing works
Miller, B. C., Sen, D. R., Al Abosy, R., Bi, K., Virkud, Y. V., LaFleur, M. W., Yates, K. B., Lako, A., Felt, K., Naik, G. S., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0312-6 · Cited by 2,087 · see citing works
Clonal replacement of tumor-specific T cells following PD-1 blockade
Yost, K. E., Satpathy, A. T., Wells, D. K., Qi, Y., Wang, C., Kageyama, R., McNamara, K. L., Granja, J. M., Sarin, K. Y., Brown, R. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0522-3 · Cited by 1,534 · see citing works
The epigenetic landscape of T cell exhaustion
Sen, D. R., Kaminski, J., Barnitz, R. A., Kurachi, M., Gerdemann, U., Yates, K. B., Tsao, H.-W., Godec, J., LaFleur, M. W., Brown, F. D., et al. (2016) · Science · doi:10.1126/science.aae0491 · Cited by 986 · see citing works
Azimi, F., Scolyer, R. A., Rumcheva, P., Moncrieff, M. D., Murali, R., McCarthy, S. W., Saw, R. P. M., & Thompson, J. F. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.8539 · Cited by 857 · see citing works
MHC-II neoantigens shape tumour immunity and response to immunotherapy
Alspach, E., Lussier, D. M., Miceli, A. P., Kizhvatov, I., DuPage, M., Luoma, A. M., Meng, W., Lichti, C. F., Esaulova, E., Vomund, A. N., et al. (2019) · Nature · doi:10.1038/s41586-019-1671-8 · Cited by 846 · see citing works
Peranzoni, E., Lemoine, J., Vimeux, L., Feuillet, V., Barrin, S., Kantari-Mimoun, C., Bercovici, N., Guérin, M., Biton, J., Ouakrim, H., et al. (2018) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1720948115 · Cited by 817 · see citing works
An intra-tumoral niche maintains and differentiates stem-like CD8 T cells
Jansen, C. S., Prokhnevska, N., Master, V., Sanda, M., Carlisle, J., Bilen, M., Cardenas, M., Wilkinson, S., Lake, R., Sowalsky, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1836-5 · Cited by 724 · see citing works
Kim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410626111 · Cited by 676 · see citing works
Fares, C. M., Allen, E. M. V., Drake, C. G., Allison, J. P., & Hu‐Lieskovan, S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_240837 · Cited by 648 · see citing works
The urgent need to recover MHC class I in cancers for effective immunotherapy
Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M., & van Hall, T. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.007 · Cited by 585 · see citing works
Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy
Poeta, V. M., Massara, M., Capucetti, A., & Bonecchi, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00379 · Cited by 585 · see citing works
Immune escape of tumors: apoptosis resistance and tumor counterattack
Igney, F. H., & Krammer, P. H. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.6.907 · Cited by 468 · see citing works
Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise
Morel, D., Jeffery, D., Aspeslagh, S., Almouzni, G., & Postel-Vinay, S. C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0267-4 · Cited by 457 · see citing works
The emerging role of epigenetic therapeutics in immuno-oncology
Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0266-5 · Cited by 433 · see citing works
Danaher, P. J., Warren, S. E., Lu, R. O., Samayoa, J. A., Sullivan, A. H., Pekker, I., Wallden, B., Marincola, F. M., & Cesano, A. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0367-1 · Cited by 413 · see citing works
Trujillo, J., Sweis, R. F., Bao, R., & Luke, J. J. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0277 · Cited by 392 · see citing works
HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story
Hicklin, D. J., Marincola, F. M., & Ferrone, S. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01451-3 · Cited by 374 · see citing works
Zheng, H., Zhao, W., Yan, C., Watson, C. C., Massengill, M. T., Xie, M., Massengill, C., Noyes, D. R., Martinez, G. V., Afzal, R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2584 · Cited by 339 · see citing works
High response rate to PD-1 blockade in desmoplastic melanomas
Eroglu, Z., Zaretsky, J. M., Hu-Lieskovan, S., Kim, D. W., Algazi, A., Johnson, D. B., Liniker, E., Kong, B., Munhoz, R., Rapisuwon, S., et al. (2018) · Nature · doi:10.1038/nature25187 · Cited by 338 · see citing works
Transcriptional insights into the CD8+ T cell response to infection and memory T cell formation
Best, J., Blair, D., Knell, J., Yang, E., Mayya, V., Doedens, A. L., Dustin, M. L., & Goldrath, A. W. (2013) · Nature Immunology · doi:10.1038/ni.2536 · Cited by 334 · see citing works
Ning, Z.-Q., Li, Z.-B., Newman, M. J., Shan, S., Wang, X.-H., Pan, D.-S., Zhang, J., Dong, M., Du, X., & Lu, X.-P. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1766-x · Cited by 303 · see citing works
Christmas, B. J., Rafie, C. I., Hopkins, A. C., Scott, B., Ma, H. S., Cruz, K. A., Woolman, S., Armstrong, T. D., Connolly, R. M., Azad, N. A., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0070 · Cited by 220 · see citing works
beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.
Hicklin, D. J., Wang, Z., Arienti, F., Rivoltini, L., Parmiani, G., & Ferrone, S. (1998) · Journal of Clinical Investigation · doi:10.1172/jci498 · Cited by 198 · see citing works
Rejection versus escape: the tumor MHC dilemma
Garrido, F., Ruiz‐Cabello, F., & Aptsiauri, N. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1947-x · Cited by 157 · see citing works
The Emerging Role of CD244 Signaling in Immune Cells of the Tumor Microenvironment
Agresta, L., Hoebe, K. H. N., & Janssen, E. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02809 · Cited by 151 · see citing works
Briere, D. M., Sudhakar, N., Woods, D. M., Hallin, J. F., Engstrom, L. D., Aranda, R., Chiang, H., Sodré, A. L., Olson, P., Weber, J. S., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2091-y · Cited by 146 · see citing works
An intact immune system is required for the anticancer activities of histone deacetylase inhibitors
West, A. C., Mattarollo, S. R., Shortt, J., Cluse, L. A., Christiansen, A. J., Smyth, M. J., & Johnstone, R. W. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0890 · Cited by 137 · see citing works
HDAC inhibitors enhance the immunotherapy response of melanoma cells
Booth, L. A., Roberts, J. L., Poklepovic, A. S., Kirkwood, J. M., & Dent, P. (2017) · Oncotarget · doi:10.18632/oncotarget.17950 · Cited by 136 · see citing works
Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
Banik, D., Moufarrij, S., & Villagra, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092241 · Cited by 134 · see citing works
Hellmann, M. D., Jänne, P. A., Opyrchal, M., Hafez, N., Raez, L. E., Gabrilovich, D. I., Wang, F., Trepel, J. B., Lee, M.-J., Yuno, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3305 · Cited by 133 · see citing works
Gong, K., Xie, J., Yi, H., & Li, W. (2012) · Biochemical Journal · doi:10.1042/bj20111685 · Cited by 130 · see citing works
de Charette, M., & Houot, R. (2018) · Haematologica · doi:10.3324/haematol.2017.184192 · Cited by 129 · see citing works
Christiansen, A. J., West, A. C., Banks, K.-M., Haynes, N. M., Teng, M. W. L., Smyth, M. J., & Johnstone, R. W. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011037108 · Cited by 113 · see citing works
HDAC inhibitors as epigenetic regulators for cancer immunotherapy
Conte, M., Palma, R. D., & Altucci, L. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.03.004 · Cited by 90 · see citing works
The anticancer effects of HDAC inhibitors require the immune system
West, A. C., Smyth, M. J., & Johnstone, R. W. (2014) · OncoImmunology · doi:10.4161/onci.27414 · Cited by 86 · see citing works
Bretz, A. C., Parnitzke, U., Kronthaler, K., Dreker, T., Bartz, R., Hermann, F., Ammendola, A., Wulff, T., & Hamm, S. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0745-3 · Cited by 83 · see citing works
A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells
Liu, L., Chen, B., Qin, S., Li, S., He, X., Qiu, S., Zhao, W., & Zhao, H. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.01.011 · Cited by 78 · see citing works
Qiao, Z., Ren, S., Li, W., Wang, X., He, M., Guo, Y., Sun, L., He, Y., Ge, Y., & Yu, Q. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.03.059 · Cited by 77 · see citing works
Zhou, Y., Pan, D., Shan, S., Zhu, J.-Z., Zhang, K., Yue, X., Nie, L., Wan, J., Lu, X., Zhang, W., et al. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.03.011 · Cited by 76 · see citing works
Arakawa, A., Vollmer, S., Tietze, J., Galinski, A., Heppt, M. V., Bürdek, M., Berking, C., & Prinz, J. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01336 · Cited by 74 · see citing works
Li, Y., Wang, Y., Zhou, Y., Li, J., Chen, K., Zhang, L., Deng, M., Deng, S., Li, P., & Xu, B. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0377-8 · Cited by 73 · see citing works
Hicks, K. C., Fantini, M. C., Donahue, R. N., Schwab, A., Knudson, K. M., Tritsch, S. R., Jochéms, C., Clavijo, P. E., Allen, C. T., Hodge, J. W., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1466018 · Cited by 70 · see citing works
Zhao, S., Guo, J., Zhao, Y., Fei, C., Zheng, Q., Li, X., & Chang, C. (2016) · Europe PMC (PubMed Central) · Cited by 68 · see citing works
Immune-resistant mechanisms in cancer immunotherapy
Kawakami, Y., Ohta, S., Sayem, M. A., Tsukamoto, N., & Yaguchi, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01611-x · Cited by 65 · see citing works
Pan, D., Yang, Q., Fu, X., Shan, S., Zhu, J.-Z., Zhang, K., Li, Z., Ning, Z., & Lu, X. (2014) · MedChemComm · doi:10.1039/c4md00350k · Cited by 61 · see citing works
Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy
Cruickshank, B. M., Giacomantonio, M., Marcato, P., McFarland, S. A., Pol, J. G., & Gujar, S. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00654 · Cited by 61 · see citing works
Zhao, B., & He, T. (2014) · Oncology Reports · doi:10.3892/or.2014.3595 · Cited by 57 · see citing works
Episensitization: Therapeutic Tumor Resensitization by Epigenetic Agents: A Review and Reassessment
Oronsky, B. T., Oronsky, N. C., Knox, S. J., Fanger, G. R., & Scicinski, J. J. (2014) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520614666140418144610 · Cited by 49 · see citing works
Modulation of Antitumor Immunity with Histone Deacetylase Inhibitors
McCaw, T. R., Randall, T. D., Forero, A., & Buchsbaum, D. J. (2017) · Immunotherapy · doi:10.2217/imt-2017-0134 · Cited by 48 · see citing works
Givechian, K. B., Wnuk, K., Garner, C. P., Benz, S. C., Garbán, H., Rabizadeh, S., Niazi, K., & Soon‐Shiong, P. (2018) · npj Genomic Medicine · doi:10.1038/s41525-018-0054-7 · Cited by 48 · see citing works
A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy
Guram, K., Kim, S. S., Wu, V. H., Sanders, P. D., Patel, S. H., Schoenberger, S. P., Cohen, E. E. W., Chen, S., & Sharabi, A. B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00491 · Cited by 47 · see citing works
Ikeda, Y., Kiyotani, K., Yew, P. Y., Sato, S., Imai, Y., Yamaguchi, R., Miyano, S., Fujiwara, K., Hasegawa, K., & Nakamura, Y. (2017) · Oncology Reports · doi:10.3892/or.2017.5536 · Cited by 45 · see citing works
Sullivan, R. J., Moschos, S. J., Johnson, M. L., Opyrchal, M., Ordentlich, P., Brouwer, S., Sankoh, S., Meyers, M. L., & Agarwala, S. S. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-ct072 · Cited by 44 · see citing works
Antitumor activity of Chidamide in hepatocellular carcinoma cell lines
Qian, H. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.858 · Cited by 43 · see citing works
Liu, Z., Ding, K., Li, L., Liu, H., Wang, Y., Liu, C., & Fu, R. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.08.023 · Cited by 41 · see citing works
Zhou, J., Zhang, C.-J., Sui, X., Cao, S., Tang, F. R., Sun, S., Wang, S., & Chen, B. (2018) · Investigational New Drugs · doi:10.1007/s10637-017-0552-y · Cited by 40 · see citing works
He, M., Qiao, Z., Wang, Y., Kuai, Q., Li, C., Wang, Y., Jiang, X., Wang, X., Li, W., He, M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166896 · Cited by 36 · see citing works
Epigenetic Strategies to Boost Cancer Immunotherapies
Barrero, M. J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061108 · Cited by 33 · see citing works
Mao, J., Li, S., Zhao, H., Zhu, Y., Hong, M., Zhu, H., Qian, S., & Li, J. (2018) · Europe PMC (PubMed Central) · Cited by 33 · see citing works
Iivanainen, S., & Koivunen, J. P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020556 · Cited by 30 · see citing works
Chidamide alleviates TGF-β-induced epithelial–mesenchymal transition in lung cancer cell lines
Lin, S., Wang, B., Lin, C., Chien, P., Wu, Y., Ko, J., & Chen, J. J. W. (2016) · Molecular Biology Reports · doi:10.1007/s11033-016-4005-z · Cited by 23 · see citing works
Hasegawa, H., Bissonnette, R. P., Gillings, M., Sasaki, D., Taniguchi, H., Kitanosono, H., Tsuruda, K., Kosai, K., Uno, N., Morinaga, Y., et al. (2016) · Cancer Science · doi:10.1111/cas.12971 · Cited by 20 · see citing works
Self-citationLiu, L., QIU, S., LIU, Y., LIU, Z., Zheng, Y. G., Su, X., CHEN, B., & Hanbing, C. H. E. N. (2016) · Neoplasma · doi:10.4149/203_150422n214 · Cited by 19 · see citing works
Immune effectors required for the therapeutic activity of vorinostat
Kepp, O., Galluzzi, L., & Kroemer, G. (2013) · OncoImmunology · doi:10.4161/onci.27157 · Cited by 15 · see citing works
West, A. C., Christiansen, A. J., Smyth, M. J., & Johnstone, R. W. (2012) · OncoImmunology · doi:10.4161/onci.18804 · Cited by 15 · see citing works
Jiang, T., Wang, F., Hu, L., Cheng, X., Zheng, Y., Liu, T., & Jia, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.20659 · Cited by 14 · see citing works
No patient left behind: The promise of immune priming with epigenetic agents
Carter, C. A., Oronsky, B. T., Roswarski, J., Oronsky, A. L., Oronsky, N. C., Scicinski, J. J., Lybeck, H., Kim, M. M., Lybeck, M., & Reid, T. R. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1315486 · Cited by 13 · see citing works
Luo, S., Ma, K., Zhu, H., Wang, S., Liu, M., Zhang, W., Liang, S., & Xu, N. (2017) · Oncology Letters · doi:10.3892/ol.2017.7060 · Cited by 13 · see citing works
Dahiya, S., Wang, L., Beier, U. H., Han, R., & Hancock, W. W. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.200.supp.54.11 · Cited by 5 · see citing works
Bissonnette, R. P., Rolland, A. P., Goodeneow, B., & Gillings, M. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.imm2016-b108 · Cited by 2 · see citing works
Self-citationKhunger, A., Rytlewski, J. A., Yusko, E. C., & Tarhini, A. A. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2541 · Cited by 1 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- [25]Mao JLS, Zhao H, Zhu Y, Hong M, Zhu H, Qian S, et al. Am J Transl Res_Effects of chidamide and decitabine on proliferation and apoptosis of leukemia cell lines. Am J Transl Res. 2018;10(8):2567–78. PMC6129529 30210693
- [30]Zhao S Guo J Zhao Y Fei C Zheng Q Li X Chang C Chidamide inhibits the viability of MDS and AML cells by suppressing JAK2-STAT3 signaling Am J Transl Res 2016 8 7 3169 27508038 PMC4969454
Cited by
Sorted by citations
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works
Resistance mechanisms to immune checkpoint inhibitors: updated insights
Al-Saafeen, B. H., Ali, B. R., & Elkord, E. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02212-7 · Cited by 207 · see citing works
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Hossain, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 196 · see citing works
Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment
Sun, Y.-C., Hong, J. H., Ning, Z., Pan, D., Fu, X., Lu, X., & Tan, J. Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.932914 · Cited by 97 · see citing works
Wang, B., Yin, H., Zhang, Y., Zhao, Q., Wang, H., Wei, J., Meng, L., Xin, Y., & Jiang, X. M. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01073-9 · Cited by 83 · see citing works
Chen, X., Zhang, W., Yang, W., Zhou, M., & Liu, F. (2022) · Aging · doi:10.18632/aging.203833 · Cited by 42 · see citing works
Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies
Sun, W., Hu, S., & Wang, X. (2024) · 癌症：英文版 · doi:10.1002/cac2.12587 · Cited by 42 · see citing works
Yang, F., Hu, T., Liu, J.-Q., Yu, X., & Ma, L. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114920 · Cited by 32 · see citing works
Ma, X., Wu, J., Wang, B., Liu, C., Liu, L., & Sun, C. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5424 · Cited by 25 · see citing works
Sedky, N. K., Hamdan, A. A., Emad, S., Allam, A. L., Ali, M. K., & Tolba, M. F. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02779-x · Cited by 23 · see citing works
PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?
Zwergel, C., Fioravanti, R., & Mai, A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103435 · Cited by 23 · see citing works
Development of DPP-4-resistant CXCL9-Fc and CXCL10-Fc chemokines for effective cancer immunotherapy
Lugassy, J., Abdala-Saleh, N., Jarrous, G., Turky, A., Saidemberg, D., Ridner-Bahar, G., Berger, N., Bar-On, D., Taura, T., Wilson, D. S., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2501791122 · Cited by 21 · see citing works
Epigenetic alterations and advancement of lymphoma treatment
Zhuang, S., Yang, Z., Cui, Z., Zhang, Y., & Che, F. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05395-z · Cited by 12 · see citing works
Harnessing histone deacetylase inhibitors for enhanced cancer immunotherapy
Hedayat, F., & Faghfuri, E. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177620 · Cited by 11 · see citing works
Narukawa, T., Yasuda, S., Horinaka, M., Taniguchi, K., Tsujikawa, T., Morita, M., Ukimura, O., & Sakai, T. (2024) · Cancers · doi:10.3390/cancers16234058 · Cited by 9 · see citing works
The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review
Ridwansyah, H., Wijaya, I., Bashari, M. H., Kartamihardja, A. H. S., & Hernowo, B. S. (2023) · Biomolecules and Biomedicine · doi:10.17305/bb.2023.8791 · Cited by 9 · see citing works
Ahronian, L. G., Sahu, S., Zhang, M., Patel, A. S., Geng, K., Bhattacharya, R., Falchook, G. S., Goldman, J. W., Spira, A. I., Punekar, S. R., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-0998 · Cited by 9 · see citing works
“Preclinically, these molecules have also demonstrated immune-mediated antitumor effects (41, 42, 45).”
A Cell-Based Screen Identifies HDAC Inhibitors as Activators of RIG-I Signaling
Fraile‐Bethencourt, E., Foss, M. H., Nelson, D., Malhotra, S. V., & Anand, S. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.837610 · Cited by 5 · see citing works
Shojaei, F., Goodenow, B., Lee, G., Kabbinavar, F., & Gillings, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.768685 · Cited by 3 · see citing works
Self-citationAdvances in understanding epigenetic impacts on dendritic cell regulation and function
Verlander, Z., Cummings, A., Brown, H. M., & Sen, R. (2022) · Clinical and Translational Discovery · doi:10.1002/ctd2.53 · Cited by 5 · see citing works
Zhang, L., Xiao, J., Li, Y., Liu, B., & Xie, L. (2024) · Cancer Management and Research · doi:10.2147/cmar.s464677 · Cited by 1 · see citing works
Ning, J. (2022) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2022.43.006887
Advances and challenges in immunotherapy for advanced esophageal squamous cell carcinoma
Wang, Y., Li, H., Zhao, P., Li, Z., & Zhang, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1739762
- Authors
- Bissonnette, R. P., Cesario, R. M., Goodenow, B., Shojaei, F., & Gillings, M.
- Affiliations
- HUYABIO International, LLC (United States) (US)
- Corresponding author
- Shojaei, Farbod
- Venue
- BMC Cancer
- Published
- 2021-08-30
- Volume
- 21
- Issue
- 1
- Pages
- 969-969
- ISSN
- 1471-2407 (ISSN-L)
- PMC
- PMC8404302
- OpenAlex
- W3196329835
- Cited by
- 24
- References
- 78
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 5 · 2023: 3 · 2022: 11
- FWCI
- 1.73
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- BMC Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Keywords
- histone deacetylase inhibitors, immune checkpoint inhibitors, PD-1/PD-L1 axis, CTLA-4, immunotherapy resistance, tumor microenvironment, combination therapy, colon cancer, B-cell lymphoma, dendritic cell function, MHC class I and II expression, oral anticancer drugs
- MeSH terms
- Immune Checkpoint Inhibitors, Animals, Benzamides, Colonic Neoplasms, Female, Humans, Immunologic Factors, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Nude, Pyridines, Tumor Cells, Cultured, Apoptosis, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Epigenesis, Genetic, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
